Gerresheimer (GXI) Q4 2023 earnings summary

Executive summary

• FY 2023 organic revenue growth was 10.4%, adjusted EBITDA growth was 17.5%, and adjusted EBITDA margin expanded 120 bps to 20.8%.

• Strong order intake, biologics demand, and investment in high-value solutions supported profitable growth and the mid-term strategy.

Financial highlights

• FY revenue was €1,990.5m, up 10.4% organically; adjusted EBITDA was €404.5m, up 17.5% organically.

• FY adjusted net income was €154.0m versus €144.7m; adjusted EPS was €4.62, up 7.1% YoY.

• Q4 revenue was €545.2m, up 5.1% organically; adjusted EBITDA was €119.3m, up 10.5%, and adjusted EPS was €1.51, up 7.4%.

Outlook and guidance

• FY 2024 guidance: organic revenue growth of 5–10%, adjusted EBITDA of €430–450m, and adjusted EPS growth of 8–12%.

• FY 2025 guidance: organic revenue growth of 10–15%, adjusted EBITDA margin of 23–25%, and adjusted EPS growth of at least 10%.

• Mid-term targets: revenue CAGR of at least 10%, adjusted EBITDA margin of at least 22%, and adjusted EPS CAGR of at least 10%.

• FY 2024 priorities include increasing biologics and injectables revenue, executing growth projects, and expanding innovative products and solutions.